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Background: Graft survival in transplant recipients depends on pharmacokinetics and on individual susceptibility
towards immunosuppressive drugs. Nevertheless, pharmacodynamic changes in T-cell functionality in response to
drugs and in relation to pharmacokinetics are poorly characterized. We therefore investigated the immunosuppressive
effect of calcineurin inhibitors and steroids on general T-cell functionality after polyclonal stimulation of whole blood
samples.
Methods: General T-cell functionality in the absence or presence of immunosuppressive drugs was determined in vitro
directly from whole blood based on cytokine induction after stimulation with the polyclonal stimulus Staphylococcus
aureus enterotoxin B. In addition, diurnal changes in leukocyte and lymphocyte subsets, and on T-cell function after
intake of immunosuppressive drugs were analyzed in 19 patients during one day and compared to respective kinetics
in six immunocompetent controls. Statistical analysis was performed using non-parametric and parametric tests.
Results: Susceptibility towards calcineurin inhibitors showed interindividual differences. When combined with steroids,
tacrolimus led to more pronounced increase in the inhibitory activity as compared to cyclosporine A. While circadian
alterations in leukocyte subpopulations and T-cell function in controls were related to endogenous cortisol levels, T-cell
functionality in transplant recipients decreased after intake of the morning medication, which was more pronounced in
patients with higher drug-dosages. Interestingly, calcineurin inhibitors differentially affected circadian rhythm of T-cell
function, as patients on cyclosporine A showed a biphasic decrease in T-cell reactivity after drug-intake in the morning
and evening, whereas T-cell reactivity in patients on tacrolimus remained rather stable.
Conclusions: The whole blood assay allows assessment of the inhibitory activity of immunosuppressive drugs in
clinically relevant concentrations. Circadian alterations in T-cell function are determined by dose and type of
immunosuppressive drugs and show distinct differences between cyclosporine A and tacrolimus. In future these
findings may have practical implications to estimate the net immunosuppressive effect of a given drug-regimen
that daily acts in an individual patient, and may contribute to individualize immunosuppression.
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Outcome and survival of transplanted organs have sig-
nificantly improved over the last decades due to the de-
velopment of new immunosuppressive drugs. Optimal
drug-dosing critically determines the balance between
allograft rejection and infectious complications. Recom-
mendations for drug-dosage are currently derived from
empirically defined regimens evaluated in large cohort
studies. In a given patient, the dosage is guided by deter-
mination of individual drug-levels in the blood, although
this does not consider pharmacodynamic aspects of a
particular drug or drug-combination or potential interin-
dividual differences in drug-susceptibility [1]. A number
of experimental approaches exist to monitor immuno-
suppressive therapy, although most approaches are not
suitable for routine clinical use or have been performed
on isolated blood cells under non-physiological condi-
tions [2,3]. We have previously shown that analysis of
T-cell functionality after stimulation of whole blood
samples with viral or bacterial antigens allows for rapid
quantitation of the potency of calcineurin inhibitors at
clinically relevant concentrations [4,5]. The immuno-
suppressive effect was quantified by comparative ana-
lysis of intracellular cytokine induction in the presence
or absence of immunosuppressive drugs [4,5]. The use
of this stimulatory assay on T-cells specific for infec-
tious antigens has the disadvantage that T-cell func-
tionality may only be analyzed in individuals who have
previously been in contact with the respective pathogen
and who have mounted an appropriate immune re-
sponse, and hence limits general use of this approach
for every patient. In addition, suitability of this ap-
proach for characterizing interindividual differences in
drug susceptibility and for analyzing inhibitory effects
of drug combinations is largely unknown.
Apart from the direct inhibitory action of a given drug
concentration, overall immune function in a patient after
drug intake is determined by complex pharmacokinetics.
We have recently shown that T-cell functionality in non-
immunocompromised healthy individuals shows circa-
dian variations that were inversely related to endogenous
cortisol levels [6]. Peak levels of interferon (IFN)-γ and
interleukin (IL)-2 from CD4 and CD8 T lymphocytes
were found at night, when endogenous levels of cortisol
were lowest [6]. Up to now, knowledge is limited as to how
natural diurnal variation in immune function by endogen-
ous cortisol is influenced by the presence of immunosup-
pressive drugs and their distinct pharmacokinetics in
transplant recipients.
In this study, we therefore aimed at evaluating a flow-
cytometric whole blood approach to characterize general
T-cell functionality and to analyze susceptibility of an in-
dividual patient’s T-cell function towards immunosup-
pressive drugs. This approach was then used tocharacterize the inhibitory effect of calcineurin inhibitors
and steroids on cellular immune function ex vivo, which
was analysed for each individual drug alone as well as in
combination. Moreover, the influence of pharmacokinet-
ics assessed by drug plasma levels on circadian fluctua-
tions in T-cell function were studied in renal transplant
recipients with high and low immunosuppressive drug
dosages and compared to the respective circadian
rhythms in healthy controls.
Methods
Patients and controls
Characterization of Staphylococcus aureus enterotoxin B
(SEB)-reactive T-cell frequency distributions was per-
formed in 30 healthy controls, 30 short-term and 30
long-term renal transplant recipients matched for age
and gender. Among them, subgroups were studied to
analyze drug-susceptibility (details specified in the leg-
ends to Figures 1 and 2). For analyses of circadian varia-
tions, 6 healthy controls (49.3 ± 15.1 years; 2 females)
and two groups of renal transplant recipients were re-
cruited. The first group included 7 patients within the
first month after transplantation (short-term; 59.1 ±
7.8 years; one female). The second group included 12
patients more than 5 months after transplantation (long-
term; 51.4 ± 12.9 years; 7 females). Details on demo-
graphics and on immunosuppressive drugs of patients
are specified in Table 1. Calcineurin inhibitors and my-
cophenolate mofetile (MMF) were taken twice daily in
the morning and in the evening, whereas methylprednis-
olone and azathioprine were taken once daily in the
morning. Long-term transplanted patients received ster-
oid dosages between 2 and 10 mg and short-term trans-
planted patients between 12 and 36 mg. All patients had
received anti-IL-2 receptor antibody induction. An
11 year-old female was recruited 9 years after heart
transplantation; she received low dose prednisolone
(2.5 mg twice daily) and the mTOR inhibitor everolimus
(0.75 mg twice daily) and was converted from cyclospor-
ine A (70 mg in the morning, 80 mg in the evening) to
tacrolimus (2 mg in the morning and evening, respect-
ively) due to recurrent rejection episodes and progres-
sive impairment of kidney function. The steroid dose
was the same before and after conversion.
Heparinized blood samples for circadian analyses were
collected at five time points spaced over a 24-hour
period (8:00 a.m., 12:00 p.m., 8:00 p.m., 12:00 a.m. and
8:00 a.m.). Samples in the child were collected at 8:00 a.m.,
10:00 a.m. and 12:00 p.m. Blood sampling at 8:00 a.m. was
performed prior to the intake of immunosuppressive drugs.
Subjects were woken up for the 12 a.m. blood collection
but were otherwise on a regular sleep-wake rhythm during
the period preceding the study. The study was approved by
the local ethics committee (Ärztekammer des Saarlandes),
Figure 1 Interindividual variability and intraindividual stability in T-cell function and different susceptibility towards calcineurin inhibitors.
(A) Inter-individual variability of SEB-reactive T-cell frequencies in 30 healthy controls (50.27 ± 13.5 years of age; 15 females), 30 short-term (51.71 ±
12.80 years of age; 15 females) and 30 long-term transplanted patients (50.16 ± 13.31 years of age; 14 females) is shown. Medians are indicated
by horizontal lines and did not differ between the groups (Kruskal-Wallis test with Dunn’s post test). Intra- and inter-assay variability in SEB-reactive
T-cell frequencies stimulated from blood samples of five healthy volunteers (P1-P5; 35.34 ± 5.54 years of age; 2 females) in the absence (B and C) or
presence of 67 ng/ml tacrolimus (D and E) or 1111 ng/ml cyclosporine A (F and G). Intra-assay variability of T-cell reactivity was determined by
repeated measurements of the same blood sample (B, D, and F). Inter-assay variability of T-cell reactivity was determined in three independently
collected blood samples (0, two and six weeks; C, E, and G). The inhibitory effect on T-cells by calcineurin inhibitors was compared in relation to the
samples treated without drugs. All drugs were solved in ethanol. Mean values are indicated as horizontal lines in panels B-G.
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gave informed consent. The concentrations of tacrolimus
and cyclosporine A were quantified by standard high-
performance liquid chromatography.
Quantitation of lymphocyte subpopulations and of T-cell
functionality
The number of leukocytes and their subpopulations
(neutrophils, monocytes, and lymphocytes) were deter-
mined from whole blood samples based on routine
blood count and differential blood counts. Lymphocyte
subpopulations were further quantified from whole
blood after combined cell-surface staining using flow-
cytometry. T-cell subpopulations were quantified by
staining of CD3, CD4, and CD8 (all antibodies from BD,
Heidelberg, Germany). B-cells and natural killer (NK)-
cells were stained using CD19 (BD), CD3, and CD16
(Dako, Hamburg, Germany). T-cell functionality was de-
termined after polyclonal stimulation of blood samples
with 2.5 μg/ml SEB (Sigma, Deisenhofen, Germany),
which elicits cytokine induction in both CD4 and CD8 T
cells in all individuals [7-9]. For some experiments,
blood samples were stimulated in the presence of im-
munosuppressive drugs. All stimulations were carried
out at 37°C as described before [6] in the presence of
1 μg/ml co-stimulatory antibodies against CD28 and
CD49d (BD). After 2 hours, cytokines were accumulated
intracellularly using 10 μg/ml brefeldin A. After a total
of 6 hours, leukocytes were fixed and erythrocytes were
lysed using BD-lysing solution. Thereafter, cells were
treated with 0.1% saponin (Sigma) for permeabilization
of leukocytes and removal of remaining erythrocytes,
and immunostained in FACS buffer (PBS, 5% FCS, 0.5%bovine serum albumin, 0.07% NaN3) in the presence of
0.1% saponin for 30 min at room temperature using sat-
urating concentrations of anti-CD4 and anti-CD69 in
combination with anti-IFN-γ or anti-IL-2 (all antibodies
from BD). CD8 T-cell reactivity was estimated based on
cells reacting in the CD4 T-cell negative lymphocyte
fraction. Samples were analyzed on a FACScan or FACS-
Canto II using Cellquest Pro or DIVA-software (BD).
Statistical analysis
Statistical analysis was performed using Prism-v5.03
software (Graphpad). Differences in SEB-reactive CD4
T-cell frequencies were analyzed using the Kruskal-
Wallis test with Dunn’s post-test. The effect of immuno-
suppressive drugs on T-cell functionality was analyzed
using the Wilcoxon test. Differences in cell numbers,
T-cell reactivity, and drug-levels during the 24 hour
period from normalized data were analyzed using re-
peated measures ANOVA with Tukey’s post-test.
Results
Inhibition of cytokine induction to quantify the potency
of calcineurin inhibitors
To establish an assay to study the effect of immunosup-
pressive drugs on T-cell functionality on an individual
basis, whole blood samples were stimulated with SEB,
which leads to polyclonal stimulation of both CD4 and
CD8 T-cells [7-9]. T-cell functionality was subsequently
assessed by quantitation of activated CD69 positive IFN-
γ producing cells. This polyclonal stimulus was chosen
as it elicited a cytokine response in all individuals tested.
As exemplified for CD4 T-cells, SEB-reactive T-cells
were detectable in both controls and patients, and
Figure 2 Steroids show a combined inhibitory activity with tacrolimus and to a lesser extent with cyclosporine A. (A) Whole blood
samples of healthy individuals (n = 10; 22.3 ± 3.2 years; 6 females) were stimulated with SEB in the absence (Mock) or presence of cyclosporine A
(CyA, 367 ng/ml and 1111 ng/ml, respectively) or tacrolimus (Tac, 22 ng/ml and 67 ng/ml, respectively) with and without steroids (MP). Bold dots
represent the means connected by lines. (B) Whole blood samples of long-term transplanted patients on cyclosporine A (n = 8; 46.2 ± 12.8 years;
2 females) and (C) on tacrolimus (n = 8; 47.3 ± 13.4 years; 2 females) were stimulated with SEB in the absence of immunosuppressive drugs (mock)
or high dose methylprednisolone (MP, 1000 ng/ml), cyclosporine A (1111 ng/ml) or tacrolimus (67 ng/ml) as well as respective combinations.
Low dose calcineurin inhibitors were not analyzed in addition, as blood from patients already included trough levels due to immunosuppressive
drug-treatment. Statistical analysis was performed using the Wilcoxon t-test. Data are expressed as median with interquartile range.
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when blood samples were analyzed at trough levels prior
to intake of immunosuppressive drugs (Figure 1A).However, as reactive T-cell frequencies showed a consid-
erable interindividual variability ranging from 0.025-
20.25%, we first used blood samples of five healthy
Table 1 Demographic characteristics of short-term and long-term transplanted patients analyzed for circadian vari-
ation of leukocyte numbers and T-cell function
Pt. # Age [years] Sex Months post transplant Category Immunosuppressive medication
1 49 Male 0.3 Short-term Tac, MP, Aza
2 65 Male 0.4 Short-term Tac, MP, Aza
3 63 Male 0.4 Short-term Tac, MP
4 49 Male 0.4 Short-term Tac, MP, Aza
5 57 Male 0.45 Short-term Tac, MP, MMF
6 62 Female 0.5 Short-term Tac, MP, Aza
7 69 Male 0.9 Short-term CyA, MP
8 71 Female 5.6 Long-term CyA, MP
9 39 Male 7.7 Long-term Tac, MP
10 48 Female 11.3 Long-term Tac, MP
11 56 Female 12.1 Long-term Tac, MP, MMF
12 60 Female 15.6 Long-term Tac, MP
13 49 Female 26.1 Long-term CyA, Aza
14 62 Male 28.6 Long-term MP, MMF
15 37 Male 28.7 Long-term Tac, MP, MMF
16 59 Male 29.1 Long-term MP, MMF
17 27 Female 57.3 Long-term CyA, MP, MMF
18 41 Female 188.0 Long-term CyA, MP
19 68 Male 253.8 Long-term MP, MMF
CyA, cyclosporine A; Tac, tacrolimus; MMF, mycophenolate mofetile; MP, methylprednisolone; Aza, azathioprine; SD, standard deviation.
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variability in the individual percentage of SEB-reactive
CD4 T-cells. As shown in Figure 1B, three independent
stimulatory reactions performed from the same samples
of a given individual yielded similar frequencies of react-
ive CD4 T-cells (intra-assay variability). This also held
true for results from three independent blood samples
drawn at different time points (0, two and six weeks,
inter-assay variability, Figure 1C). Thus, although inter-
individual variability of SEB-reactive T-cell frequencies
was high (Figure 1A), the percentage of SEB-reactive
T-cells in a given individual was stable. This stability
was considered as an essential prerequisite to subse-
quently use this stimulatory approach to quantify the
inhibitory effects of immunosuppressive drugs.
To assess intra-individual variability in the susceptibil-
ity towards immunosuppressive drugs, the same blood
samples were treated with either 67 ng/ml tacrolimus or
1111 ng/ml cyclosporine A. As with overall frequencies
of SEB-reactive CD4 T-cells, the inhibitory effect of the
two drugs on T-cell function only showed low intra-
(<5.0%) or inter-assay coefficients of variation (<6.2%,
Figure 1D-G). Of note, however, the inhibitory effect of
a drug did show interindividual variability. The differ-
ence in drug-susceptibility was similar for both calcine-
urin inhibitors and was most striking for control
subject P4, who had the highest percentage of reactiveCD4 T-cells and whose reactivity was least affected by
either drug. Similar results were found for CD4 nega-
tive lymphocytes that were quantified as an estimate of
CD8 T-cell reactivity (intra- <5.0% and inter-assay coef-
ficient of variation <8.1%, data not shown). Taken to-
gether, susceptibility towards calcineurin inhibitors
shows inter-individual differences. The low intra- and
inter-assay variability suggests that the cytokine-based
whole blood assay may be used to reliably quantify the
effect of immunosuppressive drugs on an individual
basis.
The two calcineurin inhibitors show differential inhibitory
effects in combination with steroids
To analyze the influence of immunosuppressive drug-
combinations on T-cell function after SEB-stimulation,
blood samples from ten healthy controls were treated
with or without 1 μg/ml methylprednisolone in the pres-
ence or absence of increasing doses of tacrolimus
(22 ng/ml and 67 ng/ml) or cyclosporine A (367 ng/ml
and 1111 ng/ml; Figure 2A). Drug concentrations were
titered to achieve an equal inhibition of SEB-reactive T-
cells (data not shown). Steroid treatment alone only led
to a median reduction in SEB-reactive CD4 T-cells by
23.5% (interquartile range (IQR) 30.1%, p = 0.002),
whereas inhibition by the two calcineurin inhibitors was
more pronounced (by 65.6%, IQR 23.1%, for 1111 ng/ml
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tacrolimus compared to mock treatment). Interestingly,
when either 367 or 1111 ng/ml cyclosporine A were
combined with steroids, there was a slight additional in-
hibition, but this was not significantly different from
cyclosporine A treatment alone (p = 0.23 and p = 0.06,
respectively). Of note, the inhibitory effect was more
pronounced for combined treatment with tacrolimus
and steroids, as the combination of either 22 or 67 ng/ml
tacrolimus with steroids led to a significant further de-
crease in reactive CD4 T-cells compared to tacrolimus
alone (p = 0.003 and p = 0.01, respectively, Figure 2A).
Thus, all three drugs reduced SEB-reactive CD4 T-cell fre-
quencies. The net inhibitory effect of steroids and tacroli-
mus was more pronounced as compared to that between
steroids and cyclosporine A.
The combined inhibitory action of immunosuppressive
drugs was also analyzed in samples from long-term
transplant recipients on a cyclosporine A or tacrolimus
based drug-regimen (8 patients in each group). To keep
the basal effect of regular drug-intake to a minimum,
whole blood samples were drawn at trough-levels in the
morning and stimulated with SEB in the presence or ab-
sence of additional 1 μg/ml methylprednisolone with
or without high-dose cyclosporine A (1111 ng/ml,
Figure 2B) or tacrolimus (67 ng/ml, Figure 2C). Meth-
ylprednisolone treatment alone led to a similar me-
dian decrease in T-cell reactivity in both groups (by
23.0%, IQR 27.2%, in patients on cyclosporine A, and
by 25.8%, IQR 16.1%, in patients on tacrolimus). In
line with results from controls (Figure 2A), the de-
crease induced by the two calcineurin inhibitors was
more pronounced (by 71.9%, IQR 24.8% and by 76.8%,
IQR 18.5%, respectively, Figure 2B and C). Likewise,
the combined treatment of samples with steroids and
cyclosporine A or tacrolimus caused a stronger inhib-
ition (by 85.9% (IQR 10.4%) and 87.1% (IQR 15.0%),
respectively) compared to treatment with the respect-
ive calcineurin inhibitor alone (p = 0.008 and p = 0.02,
respectively). Thus, all three drugs led to a significant
reduction in SEB-reactive CD4 T-cell frequencies in
both controls and patients and combination of cal-
cineurin inhibitors with steroids increased the inhibi-
tory effect over that observed for each drug alone.
Controls and transplant recipients differ in the circadian
rhythm of cell counts
As both T-cell numbers and their functionality are influ-
enced by circadian rhythm [6], we first studied the influ-
ence of iatrogenic immunosuppression on circadian
variation of leukocyte numbers and their subsets. To
study the effect of different overall drug-levels, the re-
spective cell numbers were quantified in short-term and
long-term transplant recipients and compared tocontrols. To allow for a robust analysis of cell popula-
tions over time, cell numbers were normalized with re-
spect to the daily mean that was calculated from all
values from one individual over the 24 h time period as
described before [6]. As shown in Figure 3, the circadian
rhythm of cell counts showed a pronounced variation
over time and differed between the three groups. Leuko-
cytes of controls had their nadir at 8:00 a.m. and their
highest peak at 8:00 p.m. (p = 0.016), whereas the
leukocyte peak in transplant patients was already ob-
served at 12:00 noon, and the increase was only signifi-
cant in long-term-transplanted patients (p = 0.007).
Long-term transplanted patients had their nadir at 8:00
in the morning, whereas lowest leukocyte counts in
short-term transplant patients were found at 8:00 in the
evening (Figure 3A). When analyzing leukocyte subpop-
ulations, a striking circadian variation was seen in neu-
trophils and lymphocytes, albeit with completely
different kinetics. The variation in neutrophil numbers
resembled that of overall leukocytes in all three groups
(Figure 3B). In contrast, lymphocyte numbers in trans-
plant recipients showed a remarkable drop four hours
after intake of immunosuppressive drugs (at 12:00 p.m.,
Figure 3D). This drop was more pronounced in short-
term transplant recipients and levels remained consider-
ably low until 8:00 p.m. Among lymphocyte subpopula-
tions, NK-cell numbers only showed marginal circadian
variations (Figure 3E), whereas patterns of B- and T-cells
largely resembled that of overall lymphocytes (Figure 3F
and G). Taken together, circadian variations in leukocyte
numbers and their subpopulations differed between con-
trols and transplant recipients. In line with increased levels
of immunosuppressive drugs, variations over time were
more pronounced in short-term transplant recipients.
Differential circadian rhythm of T-cell function in transplant
recipients and healthy controls
To assess circadian changes in T-cell functionality in
controls and transplant recipients over a 24 h time
period, blood samples were stimulated with SEB and an-
alyzed for the induction of CD69 and the cytokines IFN-
γ and IL-2. In controls, the number of IFN-γ producing
T-cells showed a continuous increase towards the even-
ing (by 55.9%, IQR 13.2%) and midnight (by 51.1%, IQR
31.4%, p < 0.0001, Figure 4A). This effect was also ob-
served for cells expressing IL-2, although the median
increase was less pronounced (by 44.0%, IQR 27.6%,
p < 0.0001, Figure 4B). In contrast, median numbers
of IFN-γ producing CD4 T-cells in transplant recipi-
ents showed a significant decrease already at 12 p.m.
(4 hours after intake of the morning medication) in
both long-term (by 57.6%, IQR 16.5%, p < 0.0001) and
short-term transplant recipients (by 120.8%, IQR
32.0%, p = 0.0001; Figure 4A). Higher drug-levels in
Figure 3 Controls and transplant recipients differ in the circadian rhythm of cell counts. Circadian rhythm of (A) leukocytes and their
subpopulations, namely (B) neutrophils, (C) monocytes, (D) lymphocytes and their subpopulations (E) NK-cells, (F) B- and (G) T-lymphocytes in
peripheral blood of healthy controls (n = 6), long-term (n = 12) and short-term transplanted patients (n = 7) was determined over 24 hours at
8:00 a.m., 12:00 p.m., 8:00 p.m., 12:00 a.m. and the following day at 8:00 a.m. Shown are the differences in cell numbers with respect to the mean
that was calculated from all values analyzed over the 24 h-time period (stippled line). The variance of cell populations at each time point with respect
to this 24 h-mean is expressed as mean ± standard error of the mean. Statistical analysis was performed using the repeated measures ANOVA with
Tukey’s post-test. Statistically significant differences are indicated with respect to the initial 8:00 a.m. sample. * p < 0.05, ** p < 0.01, *** p < 0.001.
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prolonged decrease in the absolute numbers of SEB-
reactive CD4 T-cells and this effect was also observed for
CD4 T-cells producing IL-2. Again, similar kinetics were
found for SEB-reactive cells among CD4-negative lympho-
cytes, which may serve as estimate of CD8 T-cell reactiv-
ity, and dynamics in percentage of cytokine-producing T
cells resembled those of absolute T cell numbers (data not
shown). Together with kinetics shown in Figure 3G, these
data indicate that both the numbers of T-cells and their
functionality differ in patients and controls, and dynamics
in T-cell functionality were more pronounced in short-
term transplant recipients.
Cyclosporine A and tacrolimus differentially affect
circadian rhythms in T-cell reactivity
To analyze potential differences in the inhibitory action
of the two calcineurin inhibitors during the 24 h period,circadian variations in T-cell functionality were separ-
ately analyzed in long-term transplant recipients who re-
ceived two daily doses of either cyclosporine A or
tacrolimus in combination with methylprednisolone
once daily. Interestingly, the absolute numbers of IFN-γ
reactive T-cells in patients on cyclosporine A showed bi-
phasic kinetics where levels were lowest 4 hours after
drug-intake (p = 0.033, Figure 5A). A similar effect was
observed for CD8 T-cell numbers (p = 0.007, Figure 5B),
and when the inhibitory effect was quantified as dynamic
changes in relative T-cells producing IFN-γ (Figure 5C
and D). In marked contrast, CD4 and CD8 T-cell num-
bers in patients on tacrolimus exhibited only a slight de-
crease at 12 p.m. (Figure 5A and B). Despite a second
dose of tacrolimus at 8 p.m., the numbers of reactive
T-cells even increased thereafter and stabilized at
12:00 a.m. and the early morning hours. Of note,
unlike marked biphasic kinetics in patients on
Figure 4 Differential circadian rhythm of T-cell function in transplant recipients and healthy controls. Circadian rhythm of SEB-reactive
CD4 T-cell numbers in peripheral blood of healthy controls (n = 6), long-term (n = 12) and short-term transplanted patients (n = 7) was determined
over 24 hours at 8:00 a.m., 12:00 p.m., 8:00 p.m., 12:00 a.m. and the following day 8:00 a.m. Shown are the differences in absolute cell numbers of
IFN-γ positive (A) and IL-2 positive (B) CD4 T-cells with respect to the mean that was calculated from all values analyzed over the 24 h-time
period (stippled line). The variance of cytokine-producing T-cells at each time point with respect to this 24 h-mean is expressed as mean ± standard
error of the mean. Statistical analysis was performed using the repeated measures ANOVA with Tukey’s post-test. Statistically significant differences are
indicated with respect to the initial 8:00 a.m. sample. *p < 0.05, **p < 0.01, ***p < 0.001.
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and CD8 T-cells in patients on tacrolimus were con-
siderably stable during the 24 h-interval (p = 0.826 and
p = 0.522, respectively, Figure 5C and D). Similar kinet-
ics were found for CD4 T-cells producing IL-2 (data
not shown). Interestingly, in line with inhibitory effects
on T-cell reactivity, corresponding cyclosporine A
levels 4 h after drug-intake in the morning and in the
evening showed a strong increase (6.01 and 4.37-fold,
respectively). In contrast, respective levels of tacroli-
mus only increased 1.89-fold in the morning and 1.28-
fold in the evening (Figure 5E).
To exclude that the difference in the inhibitory effects
of the two calcineurin inhibitors were due to variations
in drug-susceptibility of an individual patient, we took
the chance to study a case of an 11 year-old heart trans-
planted girl before and after conversion from cyclospor-
ine A to tacrolimus to due to recurrent rejection
episodes and progressive decline of kidney function.
Conversion was clinically indicated and offered a unique
opportunity to analyze the effect of cyclosporine A and
tacrolimus on T-cell cytokine induction in two series of
three sequential whole blood samples drawn from one
patient. In line with other patients on cyclosporine A
(Figure 5), the percentage of SEB-reactive CD4 T-cells
producing IFN-γ, IL-2 or both cytokines decreased
4 hours after intake of cyclosporine A, whereasrespective T-cell frequencies remained stable after intake
of tacrolimus (Figure 6A and B). Corresponding levels of
cyclosporine A showed a 1.74-fold increase (from 278 to
484 ng/ml), whereas the respective tacrolimus levels
showed a 1.28-fold increase only (from 9 to 11.6 ng/ml).
Thus, although only based on one case, these data fur-
ther corroborate the differential effect of the two cal-
cineurin inhibitors on the circadian rhythm of T-cell
functionality.
Discussion
Overall immune function in patients after transplant-
ation may be influenced by both immunosuppressive
drugs as well as by the endogenous circadian rhythm of
the immune response. In this study, we show that T-cell
function and individual susceptibility towards immuno-
suppressive drugs can be analyzed directly from whole
blood. When analyzing drug-combinations ex vivo, a
combined inhibitory activity was observed for steroids in
combination with tacrolimus but to a lesser extent in
combination with cyclosporine A. Moreover, transplant
recipients on a calcineurin inhibitor-based drug-regimen
show marked circadian variations in both T-cell numbers
and function that differ from those found in healthy
controls. Whereas the circadian rhythm of T-cell num-
bers and function in controls mainly depend on en-
dogenous cortisol production [10], the circadian rhythm
Figure 5 Cyclosporine A and tacrolimus differentially affect circadian rhythms in T-cell reactivity. Circadian rhythm of SEB-stimulated CD4
and CD8 T-cells in the peripheral blood of long-term transplanted patient taking cyclosporine A (n = 4) or tacrolimus (n = 5) determined over
24 hours at 8:00 a.m., 12:00 p.m., 8:00 p.m., 12:00 a.m. and the following day 8:00 a.m. Shown are the differences in absolute cell numbers of IFN-γ
positive (A) CD4 and (B) CD8 T-cells with respect to the mean that was calculated from all values analyzed over the 24 h-time period (stippled line). In
addition, relative CD4 (C) and CD8 (D) T-cell frequencies are shown. The variance of cytokine-producing T-cells at each time point with respect to this
24 h-mean is expressed as mean ± standard error of the mean. (E) Corresponding levels of calcineurin inhibitors in ng/ml determined from peripheral
blood of the patients. Statistical analysis was performed using the repeated measures ANOVA with Tukey’s post-test. Statistically significant differences
are indicated with respect to the 8:00 a.m. and 8:00 p.m. samples after drug-intake. The intake of calcineurin inhibitors (CNI) alone or in combination
with methylprednisolone (MP) is indicated. *p < 0.05, **p < 0.01.
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and level of immunosuppressive drugs. Interestingly, as
with in vitro analyses, the two calcineurin inhibitors dif-
fer in their circadian effect on T-cell function when
combined with steroids in vivo. Whereas T-cell function
in patients on a cyclosporine A-based regimen showed
pronounced biphasic kinetics with nadirs 4 h after intake
of the respective morning and evening doses, T-cell
functionality in patients on tacrolimus was rather stable
over a period of 24 hours and only showed a slight sup-
pression after drug-intake in the morning.
This study explored the use of a pharmacodynamic ap-
proach of immunosuppressive drug-monitoring, where
whole blood cells were induced to produce cytokines
after polyclonal stimulation in the presence or absence
of individual drugs or their combinations. Although viral
antigens are also suitable stimuli to assess the inhibitory
action of immunosuppressive drugs [6,5,4], SEB waschosen as a universally applicable stimulus that elicited a
T-cell response in all patients. In addition, T-cell fre-
quencies stimulated by SEB were generally higher than
those observed after pathogen-specific immunity which
allows for a better characterization of the inhibitory ef-
fects by immunosuppressive drugs. Of note, as with
other stimuli, the net percentage of SEB-reactive T-cells
per se does not directly provide any information on indi-
vidual immune function, as SEB-reactive T-cell frequen-
cies are interindividually variable. Instead, changes in
SEB-reactive T-cell functionality in response to immuno-
suppressive drugs for each individual should be related
to T-cell frequencies determined at trough levels or in
the absence of drugs or dynamic changes should be
assessed over time in relation to the level of immuno-
suppression. The whole blood assay used in this study
has advantages over the use of isolated lymphocytes in
culture medium, as the ratio between plasma protein-
Figure 6 T-cell function after drug-intake shows different dynamics after conversion from cyclosporine A to tacrolimus. (A) Dot plots
above show SEB-stimulated CD4 T-cells producing IL-2 (upper left quadrant) or IFN-γ (lower right quadrant) or both cytokines (upper right quadrant)
before (8:00 a.m.) and after (10:00 a.m. and 12:00 p.m.) intake of cyclosporine A (upper panel) or tacrolimus (lower panel). Percentages of reactive CD4
T-cells are indicated in the corresponding quadrants. Kinetics of SEB-reactive T-cells producing the cytokine IFN-γ (circles, corresponding to cells in the
two upper quadrants) and IL-2 (squares, corresponding to cells in the two right quadrants) at 8:00 a.m., 10:00 a.m. and 12:00 p.m. under cyclosporine A
and after conversion to tacrolimus are shown in panel (B). Corresponding drug-levels are indicated.
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reflects physiological conditions, and drugs can be ana-
lyzed in clinically relevant concentrations [11]. More-
over, as temperature affects the free concentration of
calcineurin inhibitors [12,13], stimulations carried out at
37°C ensured drug distributions comparable with those
observed in vivo. The assay may be suitable for pharma-
codynamic monitoring, as in vitro immunosuppressive
drugs induced a dose-dependent decrease in thepercentage of cytokine-producing cells with a low
intra- and inter-assay variability. In addition, as exem-
plified for calcineurin inhibitors, there was a marked
interindividual difference in drug-susceptibility. This is
of clinical relevance as despite pharmacokinetic moni-
toring, patients frequently experience toxicity or lack of
efficiency [14], which could be balanced by pharmaco-
dynamic assessment of immunosuppressive drugs on
T-cell function.
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their immunosuppressive properties by inhibiting the
phosphatase activity of calcineurin, major differences
exist in terms of molecular structure, side-effect profile
[15,16] and clinical outcome [14]. Differences in the in-
hibitory action on T-cell function were also found when
combined with steroids in vitro, as the combined effect
with tacrolimus was more pronounced as compared to
that of steroids and cyclosporine A. This may be rec-
onciled with the clinical evidence that steroid-resistant
rejections are more frequently observed under cyclo-
sporine A than under tacrolimus therapy. In addition,
steroid-resistant rejections on a cyclosporine A-based
regimen may successfully be treated by sole conversion
to tacrolimus, which may be related to its higher in-
hibitory activity with steroids [17].
To further elucidate potential differences in the effect
of immunosuppressive drug-combinations on circadian
rhythms of T-cell numbers and functionality, trans-
planted patients were analyzed before and after the re-
spective morning and evening doses of cyclosporine A
and tacrolimus. Steroids were taken in the morning only.
In general, circadian rhythm of T-cell numbers and re-
activity differed from that in healthy controls [6]. Im-
munosuppressive drugs altered the circadian rhythm of
T-cell counts and reactivity in a dose dependent manner,
as short-term transplanted with higher drug-dosages had
more pronounced circadian alterations than long-term
transplanted patients. The quantitative decrease of CD4
and CD8 T-cell numbers after the morning dose of
drugs is in line with results obtained after intravenous
application of methylprednisolone, where the nadir of
lymphocyte counts was detected around noon 4–8 hours
after infusion [18].
Our study is limited by the fact that we did not per-
form detailed pharmacokinetic profiling to determine
potential individual differences in peak levels of drugs
after intake over time. However, pharmacodynamic char-
acteristics of T-cell functionality largely corresponded to
the pharmacokinetic course of drugs in that tacrolimus
had lower peak levels and a flatter blood concentration
curve than cyclosporine A. In line with previous reports
[19], peak concentrations of both drugs were higher
after drug-intake in the morning than in the evening
which may result from variations in drug-adsorption,
metabolism and elimination [20]. In this respect, the in-
take of calcineurin inhibitors under fasting conditions in
the morning results in more extensive drug-exposure
and shorter time to peak concentrations than under fed
condition in the evening [21-23]. Hence, apart from the
additional activity of steroids in the morning, the differ-
ences in T-cell reactivity in the morning and evening
may at least in part be due to slight differences in re-
spective drug-levels at the two time points. Additionaldifferences were observed in the pharmacodynamics of
cyclosporine A and tacrolimus which were most obvious
when T-cell functionality was studied after drug-intake
in the evening that was not accompanied by steroids.
Whereas the percentage of reactive T-cells remained ra-
ther stable or even increased after intake of tacrolimus,
their levels showed a significant decrease after intake of
cyclosporine A. A similarly pronounced decrease in T-
cell frequencies was observed when cyclosporine A was
taken together with steroids in the morning. In line with
in vitro results, this indicated that steroids did not show
any pronounced synergistic activity with cyclosporine A.
In contrast, combined treatment of steroids with tacroli-
mus did show a stronger inhibitory activity as compared
to each drug alone, which is illustrated by the decrease
in reactive T-cell frequencies after the morning medica-
tion, while no decrease was observed after intake of ta-
crolimus only.
The effectiveness and toxicity of many drugs vary de-
pending on dosing time [24-27] and constitutes the ra-
tionale for pharmacotherapy [28]. As animal studies
have already shown marked differences in graft survival
according to timing of drug-treatment [29,30], know-
ledge on how diurnal alterations in T-cell function are
modulated by immunosuppressive drugs in humans may
be translated into clinical practice to identify drug-
regimens where circadian dynamics closely reflect nat-
ural variations in non-immunocompromized individuals
with highest T-cell reactivity around midnight. Based on
the results of this study, this functional profile is most
closely achieved in long-term transplant recipients on a
tacrolimus-based regimen. Our patients were all on a
twice daily regimen of tacrolimus. In this context, it is
tempting to speculate whether the profile of patients on
a once daily regimen may even more closely resemble
that of non-immunocompromized individuals. Know-
ledge of the circadian rhythm of T-cell numbers and
their reactivity may also have practical consequences for
the use of immune-based assays to study pathogen-
specific immune responses in transplanted patients
[31-33]. Whereas the kinetics of the healthy controls are
considerably stable during routine clinical hours from
the morning through the noon [6], reactive CD4 T-cells
of short-term transplanted patients may vary on average
from 76.19% to −57.38% of the daily mean between
morning and noon. When using these assays in clinical
practice, this emphasizes the need for standardized tim-
ing of blood collection in transplanted patients, espe-
cially during routine hours at daytime. Due to the
different kinetics of tacrolimus and cyclosporine A, this
is even more important for patients on cyclosporine A.
Limitations of our study include the fact that we did
not simultaneously analyze clock genes to elucidate
whether their expression pattern undergoes similar
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small sample size may be considered as a further limita-
tion. Nevertheless all subjects in the respective groups
showed a considerably homogenous pattern of T-cell
functionality. An influence of proliferation inhibitors on
circadian rhythm of T-cell function described in this
study is unlikely, as drugs such as MMF and azathio-
prine do not have any effect on the early cytokine induc-
tion after 6 hours [34]. Hence, further studies with
different readouts are needed to monitor individual sup-
pressive activity of anti-proliferative drugs. As a further
limitation, we were unable to study the effects of higher
doses of cyclosporine A on diurnal variations of T-cell
reactivity in short-term transplant recipients, as most of
these patients received a tacrolimus-based drug-regimen
in our transplant center. Finally, the study was not de-
signed and the sample size is not powered to assess graft
survival in relation to individual susceptibility towards
immunosuppressive drugs, which should be addressed in
future prospective studies.
Conclusion
The inhibitory effect of immunosuppressive drugs and
their combinations may be analyzed on an individual
basis. In addition, the two calcineurin inhibitors differen-
tially affect diurnal variations of T-cell reactivity with
less variability of T-cell inhibition in the daily course
with tacrolimus. Together, this knowledge may improve
estimations on the net immunosuppressive effect of a
given drug-combination that daily acts in an individual
patient, and may help to optimize drug-dosage and tim-
ing of drug-intake to individualize immunosuppression
with potentially less side-effects.
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